Amikacin



Amikacin
Systematic (IUPAC) name
(2S)-4-amino-N-[(2S,3S,4R,5S)-5-amino-2-
[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-
6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,
4S,5R,6R)-6-(aminomethyl)-3,4,5-trihydroxy-
oxan-2-yl]oxy-3-hydroxy-cyclohexyl]-2-hydroxy-
butanamide
Identifiers
CAS number 37517-28-5
ATC code S01AA21
PubChem 441188
DrugBank APRD00550
Chemical data
O13 
Mol. mass 585.603 g/mol
Pharmacokinetic data
Bioavailability  ?
Protein binding 0-11%
Metabolism  ?
Half life 2-3 hours
Excretion Renal
Therapeutic considerations
Pregnancy cat.

D(AU) C(US)

Legal status

℞-only(US)

Routes Intramuscular, intravenous

Amikacin is an proteins vital to its growth.

Administration

Amikacin may be administered once or twice a day but must be given by the intravenous or intramuscular route, which tends to be painful. There is no oral form available. Dosage must be adjusted in people with kidney failure.

Uses

Amikacin is most often used for treating severe, hospital-acquired infections with multidrug resistant Gram negative bacteria such as Pseudomonas aeruginosa, Acinetobacter, and Enterobacter.

Amikacin may be combined with a beta-lactam antibiotic for empiric therapy for people with neutropenia and fever.

Side effects

Side effects of amikacin are similar to other aminoglycosides. Kidney damage and hearing loss are the most important effects. Because of this potential, blood levels of the drug and markers of kidney function (creatinine) may be monitored.

References

  • Edson RS, Terrell CL. The aminoglycosides. Mayo Clin Proc. 1999 May;74(5):519-28. Review. PMID 10319086
v • d • e
Metronidazole
v • d • e
Netilmicin • Sisomicin
OtherAmikacin
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Amikacin". A list of authors is available in Wikipedia.